Soluble HLA measurement in saliva and cerebrospinal fluid in Caucasian patients with multiple sclerosis: a preliminary study

BACKGROUND: Measurement of soluble HLA in body fluids has a potential role in assessing disease activity in autoimmune disorders. METHODS: We applied a solid phase, enzyme-linked immunoassay to measure soluble HLA class I (sHLA-I) and class II (sHLA-II) molecules in the saliva and cerebrospinal fluid (CSF) in 13 untreated patients with relapsing-remitting form of multiple sclerosis (MS). For comparison purposes, we also studied saliva from 53 healthy subjects. RESULTS: Saliva from normal controls had detectable sHLA-I levels in 41 of 53 individuals studied, with values ranging from 9–100 ng/ml (mean = 41 ± 2.8 ng/ml). sHLA-I was undetectable in the saliva in 11 of 13 MS patients, and in none of the CSF specimens. In contrast, mean sHLA-II concentration in the saliva of MS patients was significantly increased compared to controls (386 ± 52 unit/ml vs. 222 ± 18.4 unit/ml, t = 8.68, P < 0.005). The mean CSF sHLA-II level (369 ± 16 unit/ml) was equivalent to the mean sHLA-II concentration measured in saliva (mean = 386 ± 52 unit/ml) (P = 0.7). In patients with brain magnetic resonance imaging (MRI) enhancing lesions (n = 5), reflective of more active disease, CSF sHLA-II averaged 356 ± 26 unit/ml compared to 380 ± 51 in saliva. Similarly, in patients with non-enhancing lesions (n = 8), CSF sHLA-II averaged 377 ± 18 unit/ml compared to 390 ± 77 unit/ml in saliva. Thus, the mean sHLA-II concentration in saliva and CSF was essentially equivalent for MS patients with or without enhancing plaques. CONCLUSION: Our data suggest that the measurement of soluble HLA in saliva, specifically sHLA-II, correlates with the level found in the CSF. Therefore, if sHLA correlates with disease activity in MS, as has been proposed, saliva measurements provide a noninvasive correlate of CSF measurement

Apolipoproteína AI e lipoproteínas de alta densidade: estrutura e papel na homeostase do colesterol celular

La apolipoproteína A-I (apoAI) es el componente proteico mayoritario de las lipoproteínas de alta densidad (HDL), cuyo nivel sérico se correlaciona inversamente con el riesgo aterogénico. Las propiedades antiaterogénicas son atribuidas en gran parte al rol protagónico que tiene en el transporte reverso de colesterol (RCT), proceso que remueve el exceso de colesterol de los tejidos periféricos. La apoAI es una proteína anfitrópica formada casi en exclusividad por a-hélices anfipáticas, y presenta una gran flexibilidad conformacional que es crucial para su ciclo funcional, en el que se interconvierte entre diferentes estados: libre, unida a membranas, o a una gran variedad de complejos lipoproteicos de diferente tamaño, morfología y composición. En este reporte se revisa el conocimiento actual sobre la estructura y propiedades de interacción con lípidos de apoAI, en relación a la biogénesis de HDL y su función en el RCT. Se trata en particular la configuración de apoAI en HDL discoidales, así como la interacción con lípidos y la importancia para la remoción celular de colesterol de un par de a-hélices anfipáticas que presentan una distribución particular de los residuos cargados y se localizan en el centro de la molécula de apoAI.Apolipoprotein A-I (apoAI) is the major protein component of high density lipoprotein (HDL), whose serum level is inversely correlated with atherogenic risk. Antiatherogenic properties are largely attributed to its key role in reverse cholesterol transport (RCT), a process that removes cholesterol excess from peripheral tissues. ApoAI is an amphitropic protein that almost exclusively contains amphipathic a-helices, and presents a large conformational flexibility that is crucial for its functional cycle, in which it inter-converts into different states: free or bound to membranes, or into a lipoprotein complex variety of different sizes, compositions and morphologies. This report reviews the current knowledge of the structure and lipid interaction properties of apoAI, in relation with HDL biogenesis and function in RCT. In particular, focus is made on the apoAI configuration in discoidal HDL; as well as on the interaction with lipids, and the importance for cellular cholesterol efflux, of an amphipathic a-helix pair having a particular distribution of the charged residues and that locate at the center of the apoAI molecule.Apolipoproteína A-I (apoAI) é o principal componente proteico das lipoproteínas de alta densidade (HDL), cujo nível sérico se correlaciona inversamente com o risco aterogênico. As propriedades antiaterogênicas são atribuídas, em grande parte, a seu papel principal no transporte reverso de colesterol (RCT), um processo que remove o excesso de colesterol dos tecidos periféricos. A ApoAI é uma proteína anfitrópica constituída quase exclusivamente por α-hélices anfipáticas, e apresenta uma grande flexibilidade conformacional que é essencial para seu ciclo funcional, no qual se interconverte entre diferentes estados: livre, ligada a membranas ou a uma grande variedade de complexos lipoproteicos de diferente tamanho, morfologia e composição. Este relatório analisa o conhecimento atual sobre a estrutura e propriedades de interação com lipídios de apoAI, com relação à biogênese de HDL e sua função no RCT. Em particular, trata-se a configuração de apoAI em HDL discoidais; bem como a interação com lipídios e a importância para a remoção celular de colesterol de um par de α-hélices anfipáticas que apresentam uma distribuição específica dos resíduos carregados e se localizam no centro da milécula de apoAI.Fil: Garda, Horacio Alberto. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico La Plata. Instituto de Investigaciones Bioquímicas de La Plata; Argentina; ArgentinaFil: Toledo, Juan Domingo.Fil: Gonzalez, Maria Cecilia.Fil: Prieto, Eduardo Daniel. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico La Plata. Instituto de Investigaciones Fisicoquímicas Teóricas y Aplicadas; ArgentinaFil: Cuellar, Luz Ángela.Fil: Cabaleiro, Laura Virginia. Consejo Nacional de Investigaciones Científicas y Técnicas. Centro Científico Tecnológico La Plata. Instituto de Investigaciones Bioquímicas de La Plata; Argentina; ArgentinaFil: Chirillano, Lucio Alfonso.Fil: Almeyra, Carla Mariel

The effects of high dose interferon-β1a on plasma microparticles: Correlation with MRI parameters

<p>Abstract</p> <p>Objectives</p> <p>We previously reported a correlation between levels of microparticles carrying CD31 (PMP ^CD31+) and disease activity in MS. However, the effects of long term (12 month) treatment with high dose, high frequency interferon-β1a (Rebif™) on plasma levels of PMP^CD31+, PMP^CD146+, and PMP^CD54+and MRI measures of disease activity have not yet been assessed.</p> <p>Methods</p> <p>During this prospective 1-year study, we used flow cytometry to measure changes in plasma microparticles (PMP) bearing CD31 (PMP^CD31+), CD146 (PMP^CD146+), and CD54/ICAM-1 (PMP^CD54+) in 16 consecutive patients with relapsing-remitting MS (RRMS) before and after 3, 6, and 12 months of subcutaneous therapy with interferon-beta1a (44 micrograms, 3X weekly). At each visit, clinical exams and expanded disability status scale (EDSS) scores were recorded.</p> <p>Results</p> <p>Plasma levels of PMP^CD31+, and PMP^CD54+were significantly reduced by treatment with IFN-β1a. PMP^CD146+appeared to decrease only at 3 months and did not persist at 6 and 12 months (p = 0.0511). In addition, the decrease in plasma levels of PMP^CD31+and PMP^CD54+levels at 12 months were associated with a significant decrease in the number and volume of contrast enhancing T1-weigthed lesions.</p> <p>Conclusion</p> <p>Our data suggest that serial measurement of plasma microparticles (PMP), particularly in the initial stages of MS (when neuro-inflammatory cascades are more intense), may serve as reliable and reproducible surrogate markers of response to IFN-β1a therapy for MS. In addition, the progressive decline in plasma levels of PMP^CD31+and PMP^CD54+further supports the concept that IFN-β1a exerts stabilizing effect on the cerebral endothelial cells during pathogenesis of MS.</p

Discovery of new companions to high proper motion stars from the VVV Survey

Accepted for publication in A&A; 14 pages, 3 figures, 6 tablesWe acknowledge support by the FONDAP Center for Astrophysics 15010003; BASAL CATA Center for Astrophysics and Associated Technologies PFB-06; the Ministry for the Economy, Development, and Tourism’s Programa Iniciativa Científica Milenio through grant P07-021- F, awarded to The Milky Way Millennium Nucleus; FONDECYT grants No. 1090213 and 1110326 from CONICYT, and the European Southern Observatory. J.C.B. acknowledge support from a Ph.D. Fellowship from CONICYT. M.G. is financed by the GEMINI-CONICYT Fund, allocated to the project 32110014. R.K. acknowledges partial support from FONDECYT through grant 1130140. E.L.M. acknowledges support from grant AyA2011- 30147-C03-03; J.B. acknowledge support from FONDECYT No. 1120601; A.N.C. acknowledges support from GEMINI-CONICYT No. 32110005 and from Comitee Mixto ESO-GOBIERNO DE CHILE. J.A.G. acknowledges support from Proyecto Fondecyt Postdoctoral 3130552, Fondecyt Regular 1110326, and Anillos ACT-86

The Fourteenth Data Release of the Sloan Digital Sky Survey: First Spectroscopic Data from the extended Baryon Oscillation Spectroscopic Survey and from the second phase of the Apache Point Observatory Galactic Evolution Experiment

The fourth generation of the Sloan Digital Sky Survey (SDSS-IV) has been in operation since July 2014. This paper describes the second data release from this phase, and the fourteenth from SDSS overall (making this, Data Release Fourteen or DR14). This release makes public data taken by SDSS-IV in its first two years of operation (July 2014-2016). Like all previous SDSS releases, DR14 is cumulative, including the most recent reductions and calibrations of all data taken by SDSS since the first phase began operations in 2000. New in DR14 is the first public release of data from the extended Baryon Oscillation Spectroscopic Survey (eBOSS); the first data from the second phase of the Apache Point Observatory (APO) Galactic Evolution Experiment (APOGEE-2), including stellar parameter estimates from an innovative data driven machine learning algorithm known as "The Cannon"; and almost twice as many data cubes from the Mapping Nearby Galaxies at APO (MaNGA) survey as were in the previous release (N = 2812 in total). This paper describes the location and format of the publicly available data from SDSS-IV surveys. We provide references to the important technical papers describing how these data have been taken (both targeting and observation details) and processed for scientific use. The SDSS website (www.sdss.org) has been updated for this release, and provides links to data downloads, as well as tutorials and examples of data use. SDSS-IV is planning to continue to collect astronomical data until 2020, and will be followed by SDSS-V.Comment: SDSS-IV collaboration alphabetical author data release paper. DR14 happened on 31st July 2017. 19 pages, 5 figures. Accepted by ApJS on 28th Nov 2017 (this is the "post-print" and "post-proofs" version; minor corrections only from v1, and most of errors found in proofs corrected

International evidence-based guidelines on Point of Care Ultrasound (POCUS) for critically ill neonates and children issued by the POCUS Working Group of the European Society of Paediatric and Neonatal Intensive Care (ESPNIC).

BACKGROUND: Point-of-care ultrasound (POCUS) is nowadays an essential tool in critical care. Its role seems more important in neonates and children where other monitoring techniques may be unavailable. POCUS Working Group of the European Society of Paediatric and Neonatal Intensive Care (ESPNIC) aimed to provide evidence-based clinical guidelines for the use of POCUS in critically ill neonates and children. METHODS: Creation of an international Euro-American panel of paediatric and neonatal intensivists expert in POCUS and systematic review of relevant literature. A literature search was performed, and the level of evidence was assessed according to a GRADE method. Recommendations were developed through discussions managed following a Quaker-based consensus technique and evaluating appropriateness using a modified blind RAND/UCLA voting method. AGREE statement was followed to prepare this document. RESULTS: Panellists agreed on 39 out of 41 recommendations for the use of cardiac, lung, vascular, cerebral and abdominal POCUS in critically ill neonates and children. Recommendations were mostly (28 out of 39) based on moderate quality of evidence (B and C). CONCLUSIONS: Evidence-based guidelines for the use of POCUS in critically ill neonates and children are now available. They will be useful to optimise the use of POCUS, training programs and further research, which are urgently needed given the weak quality of evidence available

Clinical and neuroimaging correlates of antiphospholipid antibodies in multiple sclerosis: a preliminary study

<p>Abstract</p> <p>Background</p> <p>The presence of antiphospholipid antibodies (APLA) in multiple sclerosis (MS) patients has been reported frequently but no clear relationship between APLA and the clinical and neuroimaging features of MS have heretofore been shown. We assessed the clinical and neuroimaging features of MS patients with plasma APLA.</p> <p>Methods</p> <p>A consecutive cohort of 24 subjects with relapsing-remitting (RR) MS were studied of whom 7 were in remission (Rem) and 17 in exacerbation (Exc). All subjects were examined and underwent MRI of brain. Patients' plasma was tested by standard ELISA for the presence of both IgM and IgG antibodies using a panel of 6 targets: cardiolipin (CL), β2 glycoprotein I (β2GPI), Factor VII/VIIa (FVIIa), phosphatidylcholine (PC), phosphatidylserine (PS) and phosphatidylethanolamine (PE).</p> <p>Results</p> <p>In exacerbation up to 80% of MS subjects had elevated titers of IgM antibodies directed against the above antigens. However, in remission, less than half of MS patients had elevated titers of IgM antibodies against one or more of the above antigens. This difference was significant, p < 0.01, for all 6 target antigens. Interestingly, none of the MS patients had elevated plasma titers of IgG against any of the target antigens tested. Correlation analysis between MRI enhancing lesions and plasma levels of APLA revealed high correlation for aPC, aPS and aFVIIa (p ≤ 0.0065), a trend for aPE and aCL (p = 0.056), and no correlation for aβ2GP1. The strongest correlation was for aFVIIa, p = 0.0002.</p> <p>Conclusion</p> <p>The findings of this preliminary study show that increased APLA IgM is associated with exacerbations of MS. Currently, the significance of this association in pathogenesis of MS remains unknown. However, systematic longitudinal studies to measure APLA in larger cohorts of patients with relapsing-remitting MS, particularly before and after treatment with immunomodulatory agents, are needed to confirm these preliminary findings.</p

The 16th Data Release of the Sloan Digital Sky Surveys : First Release from the APOGEE-2 Southern Survey and Full Release of eBOSS Spectra

This paper documents the 16th data release (DR16) from the Sloan Digital Sky Surveys (SDSS), the fourth and penultimate from the fourth phase (SDSS-IV). This is the first release of data from the Southern Hemisphere survey of the Apache Point Observatory Galactic Evolution Experiment 2 (APOGEE-2); new data from APOGEE-2 North are also included. DR16 is also notable as the final data release for the main cosmological program of the Extended Baryon Oscillation Spectroscopic Survey (eBOSS), and all raw and reduced spectra from that project are released here. DR16 also includes all the data from the Time Domain Spectroscopic Survey and new data from the SPectroscopic IDentification of ERosita Survey programs, both of which were co-observed on eBOSS plates. DR16 has no new data from the Mapping Nearby Galaxies at Apache Point Observatory (MaNGA) survey (or the MaNGA Stellar Library "MaStar"). We also preview future SDSS-V operations (due to start in 2020), and summarize plans for the final SDSS-IV data release (DR17).Peer reviewe